• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    ajh.pdf
    Size:
    1.787Mb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Schwaab, J
    Naumann, N
    Luebke, J
    Jawhar, M
    Somervaille, Tim CP
    Williams, Mark S
    Frewin, R
    Jost, PJ
    Lichtenegger, FS
    La Rosee, P
    Storch, N
    Haferlach, T
    Horny, HP
    Fabarius, A
    Haferlach, C
    Burchert, A
    Hofmann, WK
    Cross, NCP
    Hochhaus, A
    Reiter, A
    Metzgeroth, G
    Show allShow less
    Affiliation
    Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
    Issue Date
    2020
    
    Metadata
    Show full item record
    Citation
    Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020.
    Journal
    American Journal of Hematology
    URI
    http://hdl.handle.net/10541/622993
    DOI
    10.1002/ajh.25825
    PubMed ID
    32279331
    Additional Links
    https://dx.doi.org/ 10.1002/ajh.25825
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1002/ajh.25825
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
    • Authors: Ribeiro BF, Miranda EC, Albuquerque DM, Delamain MT, Oliveira-Duarte G, Almeida MH, Vergílio B, Silveira RA, Oliveira-Duarte V, Lorand-Metze I, De Souza CA, Pagnano KB
    • Issue date: 2015 Aug
    • Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
    • Authors: Zhao Y, Luo Y, Shi J, Cai Z, Huang H
    • Issue date: 2014 Jun
    • Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    • Authors: Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J
    • Issue date: 2015 Mar
    • Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
    • Authors: Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A
    • Issue date: 2015 Feb
    • Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    • Authors: Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP
    • Issue date: 2011 Sep
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.